Active Ingredient History
Trimetazidine is a drug for angina pectoris sold under many brand names. Trimetazidine is described as the first cytoprotective anti-ischemic agent developed and marketed by Laboratoires Servier (France). It is an anti-ischemic (antianginal) metabolic agent of the fatty acid oxidation inhibitor class, meaning that it improves myocardial glucose utilization through inhibition of fatty acid metabolism. Wikipedia
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute-On-Chronic Liver Failure (Phase 1)
Amyotrophic Lateral Sclerosis (Phase 2)
Angina, Unstable (Phase 4)
Blood Platelet Disorders (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Cardiomyopathy, Hypertrophic (Phase 2)
Cardiotoxicity (Phase 2/Phase 3)
Coronary Artery Disease (Phase 4)
Coronary Disease (Phase 4)
COVID-19 (Phase 2)
Diabetes Mellitus (Phase 3)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Nephropathies (Phase 2)
Heart Failure (Phase 1)
Heart Failure, Diastolic (Phase 4)
Hypertension, Pulmonary (Phase 3)
Medicine, Chinese Traditional (Phase 4)
Microcirculation (Phase 4)
Motor Neuron Disease (Phase 2)
Myocardium (Phase 2)
Percutaneous Coronary Intervention (Phase 4)
Respiratory Distress Syndrome (Phase 2)
Vascular Resistance (Phase 4)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue